Prevalence of HIV-1 drug resistance mutations among Spanish prison inmates

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 25, Issue 11, 2006, Pages 695-701

  Garcia Guerrero J ^a,b   Saiz De La Hoya P ^c   Portilla, J ^d   Marco, A ^e   Sanchez Paya J ^d   Moreno, S ^f   Garcia Benasach I ^g,h   Ruiz Rodriguez F ^g,i   Bedia, M ^g,j   Herrero, A ^g,k   Castrillo, N ^g,l   Serrano, J ^g,m   Martin M ^g,n   Hidalgo, L ^g,o   Gallego, C ^g,p   Zarauza, V ^g,q   Araujo, R ^g,r   Esteban, A ^g,s  

^a Medical Services   (Spain)

^b Fontcalent Prison ^*  (Spain)

^c Medical Services   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g Centro Penitenciario de Castellon   (Spain)

^h A Lama Prison   (Spain)

ⁱ Albolote Prison   (Spain)

^j Foncalent Prison   (Spain)

^k Castellón I Prison   (Spain)

^l El Dueso Santoña Prison   (Spain)

^m Madrid II Prison   (Spain)

ⁿ Madrid V Prison   (Spain)

^o Asociación de Familiares de Personas Con Alzheimer   (Spain)

^p Quatre Camins Prison   (Spain)

^q Sevilla I Prison   (Spain)

^r Picassent Prison   (Spain)

^s Zuera Prison   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTICENTER STUDY; MULTIDRUG RESISTANCE; PREVALENCE; PRIORITY JOURNAL; PRISONER; RANDOMIZED CONTROLLED TRIAL; SPAIN; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN;

EID: 33751347544     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-006-0206-z     Document Type: Article

References (26)

1. Wainberg MA, Friedland G (1998) Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 279:1977-1983
2. Hirsch MS, Conway B, D'Aquila RT et al (1998) Antiretroviral resistance testing in adults with HIV infection: implications for clinical management. JAMA 279:1984-1991
3. Hirsch MS, Brun-Vezinet F, D'Aquila RT et al (2000) Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an international AIDS society - USA panel. JAMA 283:2417-2426
4. Gómez-Cano M, Rubio A, Puig T et al (1998) Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-1 infected patients in Spain. AIDS 12:1015-1020
5. Puig T, Pérez-Olmeda M, Rubio A et al (2000) Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group. AIDS 14:727-732
6. Gallego O, Ruiz L, Vallejo A; ERASE-3 Group (2001) Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. AIDS 15:1894-1896
7. Caylá JA, Marco A, Bedoya A et al (1995) Differential characteristics of AIDS patients with a history of imprisonment. Int J Epidemiol 24:1188-1196
8. García-Guerrero J, Herrero A, Vera E et al (2002) Mutaciones de resistencia de virus de la inmunodeficiencia humana tipo 1 en pacientes no tratados de los centros penitenciarios de la Comunidad Valenciana. Estudio REPRICOVA. Med Clin (Barc) 118:247-250
9. García-Guerrero J, Herrero A, Bedia M; y Grupo REPRICOVA (2004) Resistencias primarias de VIH en una población penitenciaria. Estudio REPRICOVA-2. Enferm Infecc Microbiol Clin 22:29-31
10. Gallego O, Corral A, de Mendoza C et al (2003) High rate of resistance to antiretroviral drugs among infected prison inmates. Med Sci Monit 9:CR269-CR273
11. Stone DR, Corcoran C, Wurcell A et al (2002) Antiretroviral drug resistance mutations in antiretroviral-naive prisoners. Clin Infect Dis 35:883-886
12. Brun Vezinet F et ANRS-AC 11 Group Resistance (2003) Régles d'interpretation du Genotype VIH. Mise á jour de l'algorithme. Available at: http://perso.club-internet.fr/pugliese
13. Johnson VA, Brun-Vezinet F, Clotet B et al (2003) Drug resistance mutations in HIV-1. Top HIV Med 11:215-221
14. Gatell JM, Blanco JL, Alcamí J et al (2001) Documento de consenso de GESIDA sobre la utilización de los estudios de resistencia en la práctica clínica. Enferm Infecc Microbiol Clin 19:53-60
15. Devereux HL, Youle M, Johnson MA et al (1999) Rapid decline in detectability of HIV-1 drug-resistance mutations after stopping therapy. AIDS 13:F123-F127
16. Brenner BG, Routy JP, Petrella M et al (2002) Persistence and fitness of multidrug-resistant human inmunodeficency virus type-1 acquired in primary infection. J Virol 76:1753-1761
17. Little SJ, Dawson K, Hellman NS, Richman DD, Frost SDV (2003) Persistence of transmitted drug-resistant virus among subjects with primary HIV-1 infection deferring antiretroviral therapy. In: Program and abstracts of the XII International HIV Drug Resistance Workshop, Los Cabos, México, June 2003, Abstract no. 115
18. Deeks S, Wrin T, Liegler T et al (2001) Virologic and inmunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-1 infected patients with detectable viremia. N Engl J Med 344:472-480
19. Weinstein MC, Goldie SJ, Losina E et al (2001) Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 134:440-450
20. Hirsch MS, Brun-Vezinet F, Clotet B et al (2003) Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an international AIDS society, USA panel. Clin Infect Dis 37:113-128
21. García-Guerrero J, Mínguez C, Herrero A et al (2004) Resistencias secundarias de VIH. Diferencias entre una población general y otra penitenciaria. Rev Esp Sanid Penit 6:33-39
22. Gutiérrez F, Moltó J, Escolano C et al (2000) Resistencias genotípicas a los fármacos antirretrovirales en fracasos terapéuticos con pautas de alta eficacia. Med Clin (Barc) 115:401-404
23. Briones C, Soriano V, González-Lahoz J (2000) Prevalence of drug-resistant HIV-1 genotypes in heavily pre-treated patients on current virological failure. AIDS 14:1659-1660
24. Knobel H, Codina C, Miró JM et al (2000) Recomendaciones GESIDA/SEP/PNS para mejorar la adherencia al tratamiento antirretroviral. Enferm Infecc Microbiol Clin 18:27-39
25. Schuurman R, Nijhuis M, van Leeuwen R et al (1995) Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine [3TC]. J Infect Dis 171:1411-1419
26. Bacheler LT, Anton ED, Kudish P et al (2000) Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 44:2475-2484